PE20080926A1 - Compuestos cb1 - Google Patents

Compuestos cb1

Info

Publication number
PE20080926A1
PE20080926A1 PE2007001418A PE2007001418A PE20080926A1 PE 20080926 A1 PE20080926 A1 PE 20080926A1 PE 2007001418 A PE2007001418 A PE 2007001418A PE 2007001418 A PE2007001418 A PE 2007001418A PE 20080926 A1 PE20080926 A1 PE 20080926A1
Authority
PE
Peru
Prior art keywords
phenyl
trifluoromethyl
ona
pyrrolidin
ethylamine
Prior art date
Application number
PE2007001418A
Other languages
English (en)
Inventor
John Mehnert Schaus
Perry Clark Heath
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20080926A1 publication Critical patent/PE20080926A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE AL COMPUESTO DE FORMULA (I) Y (IA) QUE SON: 3-[1-METIL-1-(6-TRIFLUOROMETIL-PIRIDIN-3-IL)-ETILAMINO]-1-(4-TRIFLUOROMETIL-FENIL)-5-(3-TRIFLUOROMETOXI-FENIL)-PIRROLIDIN-2-ONA Y (3R,5R)-3-[1-METIL-1-(6-TRIFLUOROMETIL-PIRIDIN-3-IL)-ETILAMINO]-1-(4-TRIFLUOROMETIL-FENIL)-5-(3-TRIFLUOROMETOXI-FENIL)-PIRROLIDIN-2-ONA RESPECTIVAMENTE. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA EN DONDE EL COMPUESTO DE FORMULA (I) O (IA) PRESENTAN UNA PUREZA OPTICA MAYOR DEL 95% EE. DICHOS COMPUESTOS SON ANTAGONISTAS O AGONISTAS INVERSOS DEL RECEPTOR CANNABINOIDE 1 (CB1) SIENDO UTILES EN EL TRATAMIENTO DE OBESIDAD, ESQUIZOFRENIA, ABUSO DE SUSTANCIAS O DEPENDENCIA DE ALCOHOL, CENSACION DE FUMAR
PE2007001418A 2006-10-23 2007-10-18 Compuestos cb1 PE20080926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23

Publications (1)

Publication Number Publication Date
PE20080926A1 true PE20080926A1 (es) 2008-07-19

Family

ID=39386481

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001418A PE20080926A1 (es) 2006-10-23 2007-10-18 Compuestos cb1

Country Status (23)

Country Link
US (2) US7998985B2 (es)
EP (2) EP2094684B1 (es)
JP (2) JP5331002B2 (es)
KR (2) KR101088236B1 (es)
CN (2) CN101528732B (es)
AR (1) AR063497A1 (es)
AT (1) ATE492543T1 (es)
AU (1) AU2007329808B2 (es)
BR (1) BRPI0717347A2 (es)
CA (2) CA2667372C (es)
CL (1) CL2007003002A1 (es)
CY (1) CY1111140T1 (es)
DE (1) DE602007011495D1 (es)
DK (2) DK2094684T3 (es)
EA (2) EA015175B1 (es)
ES (2) ES2398388T3 (es)
MX (2) MX2009004053A (es)
PE (1) PE20080926A1 (es)
PL (2) PL2099784T3 (es)
PT (2) PT2099784E (es)
SI (2) SI2099784T1 (es)
TW (1) TW200825067A (es)
WO (2) WO2008070306A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR063497A1 (es) * 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
DK2280961T3 (da) * 2008-04-22 2012-08-27 Lilly Co Eli 1,5-diphenyl-pyrrolidin-2-on-forbindelser som cb-1-ligander
JP5539322B2 (ja) * 2008-04-22 2014-07-02 イーライ リリー アンド カンパニー Ｃｂ−１リガンドとしての１，５−ジフェニル−ピロリジン−２−オン化合物
WO2010057000A2 (en) * 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Neuraminidase inhibitors and uses thereof
BR112013000841A2 (pt) * 2010-07-15 2016-06-07 Oleg Lliich Epshtein composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2022132803A1 (en) * 2020-12-14 2022-06-23 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
DK1725536T3 (da) 2004-02-19 2009-02-16 Solvay Pharm Bv Imidazolin-derivater med CB1-antagonistisk aktivitet
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
AR063497A1 (es) * 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento

Also Published As

Publication number Publication date
US7998985B2 (en) 2011-08-16
DE602007011495D1 (de) 2011-02-03
KR101088236B1 (ko) 2011-11-30
KR101088229B1 (ko) 2011-11-30
CA2667372A1 (en) 2008-06-12
JP2010507590A (ja) 2010-03-11
CY1111140T1 (el) 2015-06-11
ATE492543T1 (de) 2011-01-15
US8168659B2 (en) 2012-05-01
PT2094684E (pt) 2011-01-28
KR20090069316A (ko) 2009-06-30
JP5331002B2 (ja) 2013-10-30
WO2008070306A3 (en) 2008-07-31
PL2099784T3 (pl) 2013-05-31
BRPI0717347A2 (pt) 2014-01-14
DK2099784T3 (da) 2013-01-14
SI2094684T1 (sl) 2011-04-29
PT2099784E (pt) 2013-01-04
EP2099784B1 (en) 2012-12-12
CA2667210C (en) 2013-09-24
EP2094684B1 (en) 2010-12-22
CN101528733B (zh) 2013-10-16
EP2099784A2 (en) 2009-09-16
AU2007329808B2 (en) 2013-11-07
CL2007003002A1 (es) 2008-06-06
JP5331001B2 (ja) 2013-10-30
WO2008070306A2 (en) 2008-06-12
DK2094684T3 (da) 2011-03-14
CA2667210A1 (en) 2008-06-12
JP2010507589A (ja) 2010-03-11
US20090275618A1 (en) 2009-11-05
CN101528732A (zh) 2009-09-09
EA200970404A1 (ru) 2009-10-30
CN101528732B (zh) 2013-04-03
EA015175B1 (ru) 2011-06-30
ES2398388T3 (es) 2013-03-15
CA2667372C (en) 2013-09-03
WO2008070305A2 (en) 2008-06-12
AR063497A1 (es) 2009-01-28
US20100016375A1 (en) 2010-01-21
EA200970405A1 (ru) 2009-12-30
AU2007329808A1 (en) 2008-06-12
AU2007329807A1 (en) 2008-06-12
CN101528733A (zh) 2009-09-09
KR20090071613A (ko) 2009-07-01
WO2008070305A3 (en) 2008-08-28
MX2009004053A (es) 2009-04-27
EP2094684A2 (en) 2009-09-02
SI2099784T1 (sl) 2013-02-28
EA015745B1 (ru) 2011-10-31
MX2009004054A (es) 2009-04-27
PL2094684T3 (pl) 2011-05-31
TW200825067A (en) 2008-06-16
ES2356025T3 (es) 2011-04-04

Similar Documents

Publication Publication Date Title
PE20080926A1 (es) Compuestos cb1
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
CL2009000256A1 (es) Imidazolinas fenil sustituidas, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, sindrome de stein-leventhal, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y dependencia a la nicotina.
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20081532A1 (es) Compuestos novedosos
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
PE20080952A1 (es) Amidas azociclicas fungicidas
PA8659301A1 (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1
CL2008003118A1 (es) Composicion fungicida que comprende (a) 1-[4-[4-[(5r)-5-(2,6-difluorofenil)-4,5-dihidro-3-isoxazolll]-2-tiazolil]-1-piperidinil]-2-[5-metil-3-(trifluorometil)-1h-pirazol-1-il]etanona y su enantiomero o mezcla de los mismos, y (b) al menos un compuesto fungicida adicional; metodo para controlar un patógeno fungico en una planta.
BR112013006336A2 (pt) (r)-(e)-2(4-(2-(5-(1-(3,5-dicloro piridin-4-il) etóxi)-1h-indazol-3-il)vinil-1-h-pirazol-1-il) etanol cristalino
CL2013000768A1 (es) Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa.
MA31675B1 (fr) Petites molecules contenant du bore
NZ597125A (en) Gpr119 agonists
PE20070592A1 (es) Derivados de prolinamida como moduladores de canales de sodio
DE602007009420D1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
NZ595073A (en) Proline derivatives as cathepsin inhibitors
PE20081884A1 (es) Inhibidores heterociclicos de la aspartil proteasa
CL2007001205A1 (es) Compuestos derivados de n-fenil-3-tio-4-fenil-azetedin-2-ona; procedimiento de preparacion; composicion farmaceutica; combinacion; uso en el tratamiento de una condicion hiperlipidemica, ateroesclerosis, alzheimer y tumores asociados a colesterol
BRPI0908406B8 (pt) Derivados de quinoxalinona, processo para a preparação dos mesmos, seu uso e composição farmacêutica
EA200970067A1 (ru) Агонисты ep2
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
NO20084007L (no) Spirokondenserte piperidiner som modulatorer av muskarinreseptorer

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed